Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$29.49 USD
-4.79 (-13.97%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $29.81 +0.32 (1.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.49 USD
-4.79 (-13.97%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $29.81 +0.32 (1.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q3 Earnings Expected to Decline
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock Holding Corporation (SRRK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -7.69% and -13.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock Holding Corporation (SRRK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -10.14% and -29.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q1 Earnings Expected to Decline
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -27.42% and -53.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Scholar Rock Holding Corporation (SRRK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More
by Zacks Equity Research
Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.
Scholar Rock Holding Corporation (SRRK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -22.64% and -40.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Scholar Rock Holding Corporation (SRRK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -480.00% and -74.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Scholar Rock Holding Corporation (SRRK) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Scholar Rock has been struggling lately, but the selling pressure may be coming to an end soon.
Is Scholar Rock Holding (SRRK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SRRK) Outperforming Other Medical Stocks This Year?
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 31.58% and 38.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -77.42% and -62.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Scholar Rock Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Scholar Rock Holding.
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
by Zacks Equity Research
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
by Zacks Equity Research
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
Sarepta Announces Agreement With Lysogene for Gene Therapy
by Zacks Equity Research
Sarepta Therapeutics (SRPT) signs license agreement with France-based Lysogene to boost its gene therapy portfolio.
Pfizer Discontinues Studies on DMD Candidate Domagrozumab
by Zacks Equity Research
Pfizer (PFE) terminates two clinical studies evaluating pipeline candidate, domagrozumab, in patients with duchenne muscular dystrophy.